Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of pegozafermin in compensated cirrhosis due to MASH
CTR20262100Phase 3Active
- Sponsor
- 89bio
- Start
- Jun 2026
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pegozafermin in metabolic dysfunction-associated steatohepatitis (MASH), Cirrhosis, sponsored by 89bio. Started Jun 2026; status: active.
02
Drugs
pegozafermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Cirrhosis
Beyond the preview
Go deeper on CTR20262100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262100.